Mesothelioma Biomarkers
| Mesothelioma Biomarkers | |
|---|---|
| Positive IHC Markers | Calretinin, WT1, D2-40 |
| Loss Markers | BAP1, MTAP (IHC) |
| Genetic Marker | CDKN2A deletion (FISH) |
| Serum Marker | Mesothelin (SMRP), fibulin-3 |
| Primary Use | Confirm diagnosis, subtype |
| Not Used For | Population screening |
Executive Summary
Mesothelioma biomarkers are the molecular and protein signals doctors use to confirm a mesothelioma diagnosis, identify its subtype, and estimate prognosis. Because mesothelioma closely resembles other cancers and benign conditions under the microscope, a biopsy alone is rarely enough — pathologists rely on a panel of biomarkers to reach a definitive diagnosis.[1]
Biomarkers fall into two groups. Tissue biomarkers are tested on a biopsy sample: positive mesothelial markers such as calretinin, WT1, and D2-40 confirm the tumor is mesothelial, while loss of BAP1 or MTAP (by immunohistochemistry) and homozygous deletion of CDKN2A (by fluorescence in situ hybridization, or FISH) distinguish malignant mesothelioma from benign, reactive mesothelial tissue. According to a 2022 review, these are the basic molecular markers for the diagnosis of mesothelioma.[2] Serum biomarkers — chiefly mesothelin (SMRP) and fibulin-3 — are measured in the blood and correlate with tumor burden, but are used as adjuncts rather than standalone or screening tests.[3]
No single biomarker diagnoses mesothelioma on its own; diagnosis rests on combining biopsy findings, an immunohistochemistry panel, and, when needed, FISH.[2] Regardless of the markers found, a mesothelioma diagnosis carries the same rights to asbestos trust fund and lawsuit compensation.[4]
At-a-Glance
Mesothelioma biomarkers at a glance:
- No single biomarker diagnoses mesothelioma — diagnosis combines biopsy, an immunohistochemistry panel, and FISH[2]
- Calretinin, WT1, and D2-40 confirm mesothelial origin — these positive markers distinguish mesothelioma from lung and other cancers[1]
- BAP1 loss signals malignancy — loss of BAP1 expression by immunohistochemistry helps separate malignant mesothelioma from benign reactive tissue[2]
- CDKN2A deletion is a key genetic marker — homozygous deletion detected by FISH is one of the basic molecular markers of mesothelioma[2]
- MTAP loss is a practical surrogate — loss of MTAP by immunohistochemistry correlates with CDKN2A deletion and is easier to test[2]
- Serum mesothelin (SMRP) tracks tumor volume — blood mesothelin levels correlate with tumor burden but are not reliable for screening[3]
- Fibulin-3 is a second serum marker — it also correlates with tumor volume, with more modest performance[3]
- Serum markers are adjuncts, not standalone tests — they support diagnosis and prognosis but do not replace tissue biopsy[3]
- Nuclear grade is a prognostic biomarker — for epithelioid tumors, nuclear grade predicts survival[5]
- Biomarkers do not change legal rights — any confirmed mesothelioma qualifies for compensation[4]
Key Facts
| Biomarker | Test Method | Role |
|---|---|---|
| Calretinin, WT1, D2-40 | Immunohistochemistry | Confirm mesothelial origin[1] |
| BAP1 loss | Immunohistochemistry | Malignant vs. benign[2] |
| MTAP loss | Immunohistochemistry | Surrogate for CDKN2A deletion[2] |
| CDKN2A deletion | FISH | Basic molecular marker of malignancy[2] |
| Mesothelin (SMRP) | Serum (blood) | Correlates with tumor volume[3] |
| Fibulin-3 | Serum (blood) | Adjunct diagnostic/prognostic marker[3] |
| Nuclear grade | Pathology (grading) | Prognostic in epithelioid disease[5] |
What Are Mesothelioma Biomarkers?
A biomarker is a measurable biological signal — a protein, a gene change, or a molecule in the blood — that indicates the presence or behavior of a disease. In mesothelioma, biomarkers answer three questions: is this cancer mesothelioma, what subtype is it, and how is it likely to behave.[1]
The need for biomarkers is driven by a diagnostic challenge. Under the microscope, mesothelioma can look like lung adenocarcinoma, ovarian or peritoneal cancers, and even benign reactive mesothelial tissue that forms in response to inflammation. Distinguishing these requires more than shape and appearance — it requires molecular evidence.[2] That is why a mesothelioma diagnosis is built on a panel of biomarkers rather than any single test. See also Mesothelioma Diagnosis.
Mesothelioma biomarkers divide into tissue biomarkers, tested on a biopsy sample, and serum biomarkers, measured in the blood. The two serve different purposes and have very different reliability.
Which Biomarkers Confirm a Mesothelioma Diagnosis?
The diagnostic workhorses are tissue biomarkers applied to a biopsy. Pathologists first use immunohistochemistry — staining the tissue for specific proteins. A positive panel of mesothelial markers, typically calretinin, WT1, and D2-40 (podoplanin), confirms that the tumor arises from mesothelial cells rather than from lung or other tissue.[1]
Confirming mesothelial origin is only half the task; the pathologist must also prove the tissue is malignant rather than a benign reactive proliferation. Here, two markers are decisive. Loss of BAP1 expression by immunohistochemistry and homozygous deletion of CDKN2A detected by fluorescence in situ hybridization (FISH) are, according to a 2022 review, the basic molecular markers for the diagnosis of mesothelioma — because benign mesothelial tissue retains these, while malignant mesothelioma frequently loses them.[2] Loss of MTAP by immunohistochemistry is a practical surrogate for CDKN2A deletion and is often used because it is simpler and cheaper to perform.[2]
Used together, this combination — positive mesothelial markers plus loss of BAP1/MTAP and CDKN2A deletion — allows pathologists to distinguish malignant mesothelioma from its many look-alikes with high confidence.
Can BAP1 and MTAP Be Tested Directly on Pleural or Peritoneal Fluid?
Yes. BAP1 and MTAP immunohistochemistry are not limited to solid tissue biopsies — both can be run directly on cell blocks prepared from a pleural or peritoneal effusion, the same fluid drawn during a routine thoracentesis or paracentesis. This matters because cytomorphology alone often cannot reliably separate atypical-but-benign reactive mesothelial cells from malignant mesothelioma cells in a fluid sample.[6]
A 2026 study of 26 pleural and peritoneal effusions containing atypical mesothelial cells found that adding BAP1 and MTAP immunohistochemistry to the cytology workup — rather than relying on cytomorphology and a limited legacy panel alone — aided the diagnosis of mesothelioma directly from the fluid specimen in 17 of the effusions evaluated after the expanded biomarker panel became available.[7] A separate 2026 review of diagnostic markers in effusion cytology confirms that BAP1 and MTAP loss by immunohistochemistry is useful both for distinguishing reactive mesothelial proliferations from mesothelioma and for differentiating mesothelioma from metastatic carcinoma in the same fluid sample.[6]
The practical significance for patients: BAP1/MTAP loss on fluid cytology can support an earlier mesothelioma diagnosis without waiting for a more invasive tissue biopsy, though pathologists still confirm the diagnosis histologically whenever a biopsy or resection specimen becomes available.[7]
What Are Serum (Blood) Biomarkers for Mesothelioma?
Blood-based biomarkers are attractive because a blood draw is far less invasive than a biopsy. The most studied is mesothelin, measured as soluble mesothelin-related peptide (SMRP). Mesothelin is a protein overexpressed by mesothelioma cells and shed into the blood, and serum SMRP levels correlate with tumor volume.[3] A second marker, fibulin-3, also correlates with tumor burden, though generally with more modest performance.[3]
These markers have real but limited roles. According to PubMed, a study of 58 patients found a strong correlation between tumor volume and serum SMRP (r = 0.61) but concluded that SMRP and fibulin-3 were not useful for following tumor response longitudinally during treatment.[3] In practice, serum biomarkers can support a diagnosis and help gauge disease burden, but they do not replace a tissue biopsy and are not accurate enough for general population screening.[3]
The practical message for patients is that a normal blood test does not rule out mesothelioma, and an abnormal one does not confirm it. Tissue remains the standard.
Which Biomarkers Predict Prognosis?
Beyond diagnosis, some biomarkers help predict how the disease will behave. The strongest is not a molecule but a pathology grade: for epithelioid mesothelioma, nuclear grade — combining nuclear atypia and mitotic count — stratifies survival, with low-grade tumors living far longer than high-grade tumors.[5] Cell type itself is also a powerful prognostic biomarker, as detailed on our Mesothelioma Cell Types page.
Molecular markers are increasingly studied for prognosis as well. BAP1 status, for example, has been linked to patient outcomes, though its main clinical role today remains diagnostic.[2] As research advances, biomarker testing is expected to play a growing part in matching patients to targeted and immunotherapy treatments. For context on how subtype shapes outlook, see Epithelioid Mesothelioma and Sarcomatoid Mesothelioma.
Do Biomarkers Affect a Mesothelioma Legal Claim?
No. Biomarkers determine how mesothelioma is diagnosed and how it is likely to behave, but they do not change a patient's legal rights. A confirmed mesothelioma diagnosis — regardless of which biomarkers were used to reach it — establishes eligibility for asbestos trust fund claims, lawsuits, and VA benefits.[4][8] The detailed pathology report, including biomarker findings, becomes part of the medical evidence supporting a claim.[9]
| ⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights. |
Frequently Asked Questions
What biomarkers are used to diagnose mesothelioma?
Diagnosis uses a panel: positive mesothelial markers (calretinin, WT1, D2-40) confirm mesothelial origin, while loss of BAP1 or MTAP and homozygous deletion of CDKN2A confirm malignancy. No single biomarker is sufficient on its own.[2][1]
What is BAP1 in mesothelioma?
BAP1 is a tumor-suppressor protein. Loss of BAP1 expression, detected by immunohistochemistry, is one of the key markers used to distinguish malignant mesothelioma from benign reactive mesothelial tissue.[2]
What is the mesothelin (SMRP) blood test?
Mesothelin, measured as soluble mesothelin-related peptide (SMRP), is a serum biomarker that correlates with mesothelioma tumor volume. It can support diagnosis and gauge disease burden, but it is not accurate enough for population screening and does not replace a biopsy.[3]
Can a blood test diagnose mesothelioma?
No. Serum biomarkers such as mesothelin and fibulin-3 are adjuncts, not standalone diagnostic tests. A normal result does not rule out mesothelioma, and a definitive diagnosis still requires a tissue biopsy with immunohistochemistry.[3][2]
Do biomarkers predict mesothelioma survival?
Some do. For epithelioid mesothelioma, nuclear grade predicts survival, and cell type is a strong prognostic factor. Molecular markers such as BAP1 are being studied for prognosis, but their main role today is diagnostic.[5][2]
Do biomarker results change my compensation eligibility?
No. Any confirmed mesothelioma diagnosis qualifies for asbestos trust fund claims, lawsuits, and VA benefits, regardless of which biomarkers were used to make the diagnosis.[4][8]
Quick Statistics
- 3 — core positive mesothelial IHC markers: calretinin, WT1, D2-40[1]
- BAP1 + CDKN2A — the basic molecular markers for diagnosing mesothelioma[2]
- MTAP loss — a practical immunohistochemistry surrogate for CDKN2A deletion[2]
- r = 0.61 — correlation between serum SMRP and mesothelioma tumor volume[3]
- 57 of 58 — patients with detectable serum mesothelin in one study[3]
- Not for screening — serum biomarkers are adjuncts, not population screening tests[3]
- Nuclear grade — a prognostic biomarker for epithelioid mesothelioma[5]
- 1 biopsy — tissue remains the diagnostic standard; no blood test replaces it[2]
|
Free, Confidential Case Evaluation Call (855) 699-5441 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice |
Related Pages
- Mesothelioma Diagnosis
- Mesothelioma Cell Types
- Epithelioid Mesothelioma
- Sarcomatoid Mesothelioma
- Mesothelioma Prognosis
- Mesothelioma
External Links
- Danziger & De Llano — Mesothelioma and asbestos trust claim attorneys.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Mesothelioma Diagnosis, Mesothelioma.net.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 Porcel JM. Pleural mesothelioma. Med Clin (Barc). 2022;159(5):240-247. PMID: 35636988. doi:10.1016/j.medcli.2022.03.007.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 Katz SI, Roshkovan L, Berger I, et al. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma tumor volumes. Lung Cancer. 2021;154:5-12. PMID: 33561782. doi:10.1016/j.lungcan.2021.01.011.
- ↑ 4.0 4.1 4.2 4.3 Mesothelioma Compensation, Danziger & De Llano.
- ↑ 5.0 5.1 5.2 5.3 5.4 Rosen LE, Karrison T, Ananthanarayanan V, et al. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018;31(4):598-606. PMID: 29327706. doi:10.1038/modpathol.2017.170.
- ↑ 6.0 6.1 Davidson B. Recently Identified Diagnostic Markers in Effusion Cytology. Acta Cytol. 2026. PMID 41961745. PubMed
- ↑ 7.0 7.1 Selvaggi SM. The Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions. Diagn Cytopathol. 2026. PMID 42163521. PubMed
- ↑ 8.0 8.1 Mesothelioma Settlements, Mesothelioma Attorney.
- ↑ Filing a Mesothelioma Claim, Danziger & De Llano.